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Treatment in sudden sensorineural hearing loss is a contentious issue, today, oral steroids are 
the most common choice and considered the best treatment option, but the use of intratympanic 
steroids has become an attractive alternative, especially in cases when systemic therapy fails, or to 
avoid the side effects of the systemic use of steroids. 
Aim: To describe the results of intratympanic methylprednisolone in idiopathic sudden sensorineural 
hearing loss after failure of oral prednisolone. 
Methods: In a prospective study fourteen patients with idiopathic sudden sensorineural hearing 
loss were treated with intratympanic methylprednisolone after failing in the treatment with systemic 
steroids. Pretreatment and post-treatment audiometric evaluations including pure tone average (PTA) 
and speech reception thresholds (SRT) were analyzed. 
Results: Ten from 14 patients treated with intra-tympanic methylprednisolone presented with hearing 
recovery > 20 dB in PTA or 20% in SRT. 
Conclusion: Three intratympanic injections of methylprednisolone improved pure-tone average 
or speech discrimination scores for a subset of sudden hearing loss subjects that failed to benefit 
from oral steroids.
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INTRODUCTION
Sudden hearing loss (SHL) may be defined as he-
aring loss of 30dB or more that occurs within three days, 
and affects three or more frequencies.1 SHL affects from 
5 to 20 persons per 100,000 every year, about 4,000 new 
cases annually in the United States of America.2 Hearing 
loss is nearly always unilateral and is commonly associated 
with tinnitus and auricular fullness. The true incidence of 
SHL in Brazil is probably underestimated because many 
patients recover their hearing within a few days and ge-
nerally do not seek medical care.
Although this entity is not one of the most common 
causes of deafness, interest in studying it remains low, 
probably due to its reversible nature in most cases.3
The etiology, natural history, and treatment of this 
entity have been a matter of discussion for several years. 
The actual number of patients that recover spontaneously 
from SHL without medical treatment remains unknown. 
The elevated rate of spontaneous recovery - over 65% in 
some studies - also confounds the reviews on the efficacy 
of a single drug or a new intervention. Any intervention 
should have improvement rates higher than a 65% assumed 
spontaneous recovery rate without therapy. The treatment 
of SHL patients varies among otology units, and there is 
no universally accepted protocol.
With no specific etiology and a short time period 
within which to provide effective therapy, generally the-
rapy is but a “ shot in the dark,” which includes several 
approaches based on hypothetical etiologies. The thera-
peutic window is short, which makes it difficult to assess 
the efficacy of detailed studies and individual agents. A 
paucity of studies limiting the time frame within which 
maximum recovery may occur - from days5,6 to months7,8 
- also complicates any evaluation of efficacy versus the 
natural history of the disease. Notwithstanding the high 
spontaneous recovery rates presented in some papers, our 
experience - and that of most authors - is that recovery 
of hearing is poor in patients that do not benefit from 
systemic corticoid therapy.9,10
Several treatment protocols have been proposed 
for treating SHL. Corticosteroids, antiviral agents, anticoa-
gulants, vasodilators, anti-inflammatory drugs, and other 
approaches have been suggested; there are reports of some 
benefit from most of these therapies. At present, the most 
commonly accepted treatment is systemic corticosteroid 
therapy. Although its efficacy has been demonstrated in 
prospective, randomized, double-blind, placebo-controlled 
studies,1,11 other studies still question the efficacy of syste-
mic corticosteroids for the treatment of SHL.2,4,8
The early and late complications of systemic cor-
ticosteroid therapy are not rare and are well-known to 
otorhinolaryngologists; this has led to investigations of to-
pical therapies in the inner ear for its conditions, including 
SHL. Intratympanic corticosteroid therapy may potentially 
provide organ-specific treatment, with high doses applied 
over the round window membrane, thereby avoiding the 
adverse effects of systemic corticosteroid therapy. As with 
other proposed treatments, the efficacy of intratympanic 
therapy for SHL needs to be determined; several studies 
have demonstrated favorable results, even after systemic 
therapy had failed.9,12-21
INTRATYMPANIC THERAPY
Itoh first reported using intratympanic corticosteroi-
ds for the treatment of inner ear disease in patients with 
Ménière’s disease in 1991.22 Silverstein (1996) first reported 
using intratympanic corticosteroid therapy for SHL. Other 
authors have also described the use of intratympanic cor-
ticosteroids for the treatment of SHL.9,12-21,23-27
Although its efficacy alone has not been proved 
definitively, intratympanic corticosteroid therapy for SHL 
is becoming more widely used. The variability among 
treatment protocols for SHL also applies to intratympanic 
corticosteroid therapy. Use of intratympanic corticosteroids 
has given rise to three main protocols for the treatment 
of SHL:
• Primary Therapy - as the first treatment for SHL, 
without systemic corticosteroids;
• Adjuvant Therapy - concomitantly with systemic 
corticosteroids, and
• Rescue therapy - started after systemic corticos-
teroid therapy has failed.
The fact that stimulated intratympanic corticos-
teroids without systemic corticosteroid therapy was the 
existence of a group of patients that did not tolerate the 
systemic side effects of high dose systemic corticosteroid 
therapy, such as diabetic patients or those with elevated 
blood pressure that was difficult to control.13,15,16
Most studies about intratympanic corticosteroids for 
treating SHL report having attempted this mode of therapy 
after systemic corticosteroid therapy has failed.9,12-21,25-27 
Two studies evaluated the effects of intratympanic corti-
costeroids as adjuvant therapy to systemic corticosteroids 
in SHL patients.23,24 There are several advantages of using 
intratympanic corticosteroids (see Frame I). The procedu-
re is well tolerated and relatively easy to perform. Most 
patients understand the concept of intratympanic therapy 
and accept it, since it may be administered in an outpatient 
setting under local (topical) anesthesia.
As opposed to systemic treatment, intratympanic 
therapy acts specifically on the affected ear. Other adverse 
effects of systemic corticosteroid therapy, besides gluco-
se intolerance and avascular hip necrosis, are insomnia, 
irritability, gastritis, and altered humor, which may be 
avoided with intratympanic therapy. The main disadvan-
tage of intratympanic corticosteroid use is lack of proof 
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about its superiority compared to systemic corticosteroid 
therapy. Other disadvantages are pain, vertigo, and the 
rare possibility of tympanic membrane perforation and 
serous otitis media.
The techniques for intratympanic corticosteroid per-
fusion in the middle ear differ in several aspects, such as 
the type of corticosteroid to be applied. Dexamethasone is 
the most common steroid used intratympanically,14,15,18-21,24,25 
followed by methylprednisolone.9,13,15,16,17,23,26,27 Reports in 
the literature differ about the concentration of solutions 
(dexamethasone: 2-4 mg/mL14,20 to 25 mg/mL;15 methyl-
prednisolone 32 mg/mL23 to 62.5 mg/mL).9,16,17 The amount 
injected in the middle ear in published papers ranges 
from 0.3 to 0.5 mL, which is approximately the middle ear 
volume. Administration modes also differ: transtympanic 
needle injection,9,13,15,19,20,17,24-27 myringotomy,13,14 myrin-
gotomy with a ventilation tube,12,23 myringotomy with a 
special perfusion needle (Micromedics, Eagan, MN),18,21 
and implantable infusion pumps in the middle ear (Round 
Window m-Cath; Durect Corp., Cupertino, CA) for conti-
nuous steroid release.16,17,21 The duration of treatment, the 
interval between injections, and the number of injections 
also differs among authors, ranging from a single dose to 
weekly transtympanic injections,9,12,14,15,18,20,23 steroid solu-
tions as drops applied by patients during several weeks,18,21 
transtympanic injections several times a week,19,23,25,26 or 
implantable infusion pumps.16,17,21
Reported complications are rare, and include pain,13 
vertigo,13,16,17,20,21 otitis media,13 perforated tympanic mem-
brane,9,21 acne,20 dysgeusia,21 chronic otitis media,21 and 
subsequent hearing loss.16,21 The purpose of this study was 
to review the experience of using 40mg/ml intratympa-
nic methylprednisolone administered in three injections 
at 48 hour intervals for SHL patients in which systemic 
corticosteroid therapy failed to improve hearing. Special 
attention was given to an evaluation of efficacy, safety, and 
the correlation with the beginning moment of treatment.
MATERIALS AND METHODS
From January to December 2008, 64 patients with a 
diagnosis of sudden sensorineural hearing loss were seen 
at the otorhinolaryngology outpatient and emergency unit 
of the University Hospital.
This study was approved by the institutional review 
board of the Medical School and the University Hospital in 
which it was carried out. All patients received information 
about the risks and expectations of therapy and signed 
a free informed consent form. A detailed clinical history 
was taken, followed by an otoneurological examination, 
and an initial audiological assessment by tonal and vocal 
audiometry, impedance testing, speech recognition rate 
(SRR), laboratory tests, and an image exam (magnetic 
resonance imaging with contrast of the inner auditory 
canal). All patients were treated with systemic therapy 
according to the local protocol (1mg/kg/day prednisolone 
for 10 days, followed by decreasing doses thereafter). No 
patient was given acyclovir antiviral therapy.
Next, salvage therapy with intratympanic methyl-
prednisolone was offered to 64 patients with a diagnosis 
of SHL, after systemic therapy failed and no improvements 
were demonstrated audiometrically. Fourteen patients 
agreed to undergo rescue therapy and signed the free 
informed consent form to be included in this study. Be-
low are the details of inclusion criteria, the audiometric 
assessment, application technique, analysis of recovery, 
and statistical analysis.
Inclusion Criteria
There were 14 patients included from an original 
group of 64 candidate patients with sudden sensorineu-
ral hearing loss; the 14 patients did not benefit from oral 
prednisolone (1mg/kg/day) for the treatment of sudden 
sensorineural hearing loss, that is, they did not improve as 
shown below under the item analysis of recovery.
Patients that did not meet the inclusion criteria 
described in Frame 2 were excluded from the study; these 
were patients with incomplete clinical data or follow-up, 
inadequate audiometry, or that had undergone more 
than three injections or that were given different concen-
trations from those standardized in this study (40mg/ml) 
were excluded. All patients with fluctuating hearing loss 
or suspected Ménière’s disease were also excluded from 
this study.
FRAME I
Transtympanic Methylprednisolone for the Treatment of Sud-
den Hearing Loss
Advantages 
Outpatient procedure 
Easily administered 
Administered soon after the diagnosis 
Relatively painless
Possible use in patients in which corticosteroids are contraindica-
ted (e.g.: immune suppression, HIV, tuberculosis, diabetes) 
High drug concentration when administered directly on the 
affected ear 
Adverse effects are rare 
Disadvantages/complications 
Tympanic membrane perforation 
Pain 
Otitis media 
Vertigo (generally temporary) 
Hearing loss
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Audiometric Analysis
All patients underwent tonal and vocal audiometry 
and speech recognition rate analysis done by audiologists 
before and after treatment. The tritonal mean was calcula-
ted based on pure tone audiometry (PTA) at 0.5, 1.0 and 
2.0 KHz. The speech recognition rate (SRR) was based 
on the percentage of correct answers for monosyllables.
Technique
Prior to any procedure, patients were oriented as to 
the risks and expectations about the procedure and signed 
a free informed consent form. EMLA cream (AstraZeneca, 
Wilmington DE) was applied for topical anesthesia. EMLA 
cream was placed in the outer ear canal and the tympanic 
membrane and left for 30 to 45 minutes, after which it 
was removed. Next, the patient’s head was placed at 45° 
towards the unaffected ear. A 40 mg/mL methylpredniso-
lone solution was warmed to body temperature in a water 
bath. About 0.3 to 0.5 mL of the solution was injected into 
the middle ear; two orifices were made with the drug ap-
plication needle (Gelco N.22), one immediately below the 
umbus (where the drug will be administered) and another 
on the postero-superior region (vent hole). No ventilation 
tubes were needed.
After intratympanic application of the steroid, the 
patient remained in the supine position and cervical 
rotation at 45° for 30 minutes to maximize exposure of 
the round window membrane to the solution. A second 
injection was done if there was any possibility that the first 
injection was not adequate. Patients were asked to avoid 
water in the treated ear for at least two weeks.
Definition of Improvement (analysis of recovery)
The criteria for defining successful recovery after 
therapy vary in the literature on intratympanic therapy. 
A 20 dB improvement at 0.5, 1 and 2KHz, or a 20% im-
provement in discrimination was enough to consider the 
intervention as successful.
Failure of oral prednisolone therapy was absence of 
improvement, as just described, after 14 days of treatment.
Statistical Analysis
The SPSS® software for Windows® v. 13.0 (2004) 
was used for the statistical analysis, which consisted of 
a sample description: sex, possible cause of the clinical 
picture, most relevant comorbidities, other symptoms, age, 
time elapsed before starting oral corticosteroid therapy 
(OCT), time elapsed before starting intratympanic corti-
costeroids (ITC). Further analysis consisted of analyzing 
the tritonal mean (PTA) before treatment, after treatment 
with OCT and after ITC. This measurement is the mean 
value of audiometry at 500, 1000 and 2000 Hz, and it was 
used to compare our results with those in the literature. 
A 20 dB audiometric decrease for PTA indicated a clinical 
improvement.
Bivariate correlations were also tested (Pearson’s 
correlation coefficient) between the initial loss in PTA (dB) 
and improvement in PTA after OCT and ITC, and the time 
elapsed until starting ITC and improvement in PTA (dB).
Finally, mean audiometric values at each frequency 
(250, 500, 1000, 2000, 3000, 4000, 6000 and 8000 Hz) 
and the speech recognition rates (SRR) before and after 
OCT and after ITC were compared using an analysis of 
variance model for repeated measures, with the purpose 
of establishing the effectiveness of therapy. The requisite 
sphericity requisite was met for all analyses (Mauchly’s W 
> 0.744, p>0.170 for all analyses), such that no correction 
method was needed to correct degrees of freedom.
The Bonferroni method was applied to correct the 
level of statistical significance for multiple comparisons. 
The statistical significance value (p-value) was 5% (p<0.05) 
throughout.
RESULTS
Patients
Tables 1 and 2 show the descriptive data of the stu-
dy sample. After applying inclusion and exclusion criteria, 
14 patients remained in the study. There were 8 female 
(57.14%) and 6 male patients (42.86%).
Image and laboratory exams revealed viral labyrin-
thitis in 2 of 14; the other 12 patients remained without a 
diagnosis after careful investigation. Their final diagnosis 
was idiopathic sudden sensorineural hearing loss (ISSHL).
Comorbidities included systemic arterial hyperten-
sion (SAH) or type 2 diabetes mellitus (DM), which were 
present in 5 patients, of which three patients had SAH and 
type 2 DM, and two had a history of increased intraocular 
pressure. Hearing did not improve in any of these 14 pa-
tients with oral prednisolone therapy. The recovery rate 
after Intratympanic therapy was 71.4%, corresponding to 
10 of 14 treated patients (see Table 1).
FRAME 2
Inclusion Criteria
• Sudden sensorineural hearing loss of at least 30 dB in three 
frequencies within three days
• No benefits from oral 1mg/kg/day prednisolone therapy during 
10 days (unilateral) or 30 days (bilateral)
• At least one audiometric test before and after oral therapy and 
another before and after intratympanic treatment
• Undergoing three intratympanic 40mg/ml methylprednisolone 
injections on alternate days
• No previous otological surgery
• No history of Ménière’s disease or fluctuating hearing before or 
after treatments (oral or intratympanic)
• No signs of acute or chronic otitis media
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It is worth noting that all patients were treated sys-
temically with prednisolone, even those with type 2 DM 
or SAH, in which a cardiologist and an endocrinologist 
approved the treatment.
The mean age was 43.79 years, ranging from 25 to 
72 years. The mean age of female patients was 38.37, and 
the mean age of male patients was 48.16 years.
Recovery
The initial tritonal mean (PTA) of 14 patients that 
did not meet the improvement criteria after oral therapy 
was 71.63 dB (median - 78.33); after fourteen days of oral 
therapy, it was 65.71 dB (median - 68.33) (see Fig. 1). One 
week after intratympanic therapy, the tritonal mean was 
40.95 dB (median - 41.67) (see Table 2 and Fig. 2).
Improved tritonal mean or SRR was seen in 71.40% 
of patients (n = 10); the mean gain among these 10 patients 
was 27.33 dB, ranging from 20 to 55 dB. Four patients 
did not improve according to our criteria; three of these 
had respectively a 5, 10 and 15 dB improvement of their 
tritonal means, and one patient had no auditory change 
after intratympanic therapy (Fig. 2).
Table 1
Description of the sample % (n)
Sex
Female 57,14 (8)
Male 42,86 (6)
Cause
ISSHL 85,7 (12)
Viral labyrinthitis 14,3 (2)
Comorbidity*
None 64,3 (9)
DM2 28,6 (4)
SAH 21,3 (3)
Glaucoma 14,3 (2)
Other symptoms
Tinnitus 85,7 (12)
Vertigo 14,3 (2)
URI symptoms 21,3 (3)
Otalgia 7,1 (1)
Improved clinical picture**
After OCT 0
After ITC 71,4 (10)
OCT: Oral Corticosteroid Therapy
ITC: Intratympanic Corticosteroid Therapy
Table 2
 Description of sample mean (EP) median
Age 43,79 (4,46) 42
Start of OCT (h) 94,29 (28,69) 72
Start of ITC (d) 16,86 (1,29) 15
PTA initial (dB) 71,67 (7,63) 78,33
PTA after OCT (dB) 65,71 (8,38) 68,33
PTA after ITC (dB) 40,95 (8,31) 41,67
h: hours; d: days
OCT: Oral Corticosteroid Therapy
ITC: Intratympanic Corticosteroid Therapy
PTA: Tritonal Mean
Figure 1. Recovery after oral corticosteroid therapy.
Figure 2. Recovery ratio following intratympanic corticosteroid therapy 
and the initial tritonal mean.
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Age Factor
Age-related recovery was analyzed for each patient. 
Pearson’s test showed that there were no statistically sig-
nificant correlations between age and improvement after 
ITC (r=0.103, p=0.726).
One patient among the 14 subjects was aged over 60 
years; this patient was aged 72 years and had SAH and type 
2 DM, a radiological and laboratory diagnosis of infectious 
viral labyrinthitis, and did not improve according to the 
abovementioned criteria. The other three patients that did 
not improve after intratympanic therapy were aged from 
25 to 55 years. The two patients that had a radiological 
and laboratory diagnosis of infectious labyrinthitis did not 
benefit from intratympanic therapy.
Recovery Related With Other Symptoms
Tinnitus was present in 12 patients (85.7%); the re-
covery rate in these patients was similar to those without 
this complaint. Vertigo was present in 2 patients (14.3%) 
and their recovery rate was 0%.
Situation of the Contralateral Ear
Normal hearing in the contralateral ear was present 
in 92.9% of patients. The recovery rate in this group was 
70%. One patient (7.1%) had abnormal hearing in the 
contralateral ear, possibly because of presbyacusis, as 
this patient was aged 72 years and did not improve with 
therapy.
Recovery Related With the Time of Onset of Symptoms 
and Therapy
(See Figs 1, 2 and 3, and Table 3) The mean time 
elapsed before starting OCT in the 14 patients was 94.29 
hours, that is, between the third and fourth day after the 
onset of symptoms (Fig. 1). The time elapsed before star-
ting intratympanic therapy was 16.86 days after the onset of 
symptoms (Fig. 3). Patients that started therapy soon after 
failures of systemic therapy was detected had an evident 
advantage. Patients that started Intratympanic therapy after 
the third week had a lower success rate compared to the 
group treated from 14 to 21 days (see Table 3).
Recovery Related With the Intensity of Hearing Loss
Pearson’s test found no statistically significant corre-
lations between initial loss (initial PTA) and improvement 
after OCT (r = -0.115, p=0.696) (Fig. 1), and between ini-
tial loss and improvement after ITC (r = 0.134, p=0.647) 
(Fig. 2).
Recovery at three moments (Initial, after OCT, and after 
ITC)
A comparison of audiometry measurement means 
in three moments (initial, after OCT and after ITC) at each 
frequency (250, 500, 1000, 2000, 3000, 4000, 6000, 8000 
Hz) revealed statistically significant differences between 
measurements at all frequencies (Fig. 4).
At 250 Hz (F2, 26= 23.863, p<0.001) the audiometry 
value after ITC was significantly lower compared to the 
initial value (p<0.001) and after OCT (p<0.001). At 500 
Table 3
Recovery related to the time elapsed before therapy was started 
and the onset of symptoms
Days before 
injection
No. of patients
Recovery of 20% 
SRR/20-dB PTA
14 - 21 d 10 9 (90%)
21-28 d 3 1 (33%)
28 d or more 1 None
Total 14 10 (71,4 %)
SRR = speech recognition rate; PTA= tritonal mean.
Figure 3. Recovery ratio following intratympanic corticosteroid therapy 
and the time elapsed before starting corticosteroid therapy.
Figure 4. Comparison between recovery and types of treatment.
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Hz (F2, 26=32.234, p<0.001), the audiometry value after 
ITC was lower than the initial value (p<0.001) and after 
OCT (p<0.001). At 1000 Hz (F2, 26=48.018, p<0.001), the 
mean audiometric value after ITC was statistically lower 
than the initial mean (p<0.001) and lower than the mean 
after OCT (p<0.001). There was also a statistically signifi-
cant difference between audiometry after OCT and initial 
audiometry (p=0.027). At 2000 Hz (F2,26=16.558, p<0.001), 
the mean audiometry values after ITC were significantly 
lower compared to the initial values (p=0.001), and after 
OCT (p=0.003).
At 3000 Hz (F2,26=17.138, p<0.001), a statistically 
significant difference was found between initial audiometry 
values and after ITC (p<0.001), and between post ITC and 
post OCT values (p=0.007). At 4000 Hz (F2, 26=14.470, 
p<0.001) the mean audiometry values after ITC were sig-
nificantly lower compared to initial values (p=0.002) and 
after OCT (p=0.011). At 6000 Hz (F2, 26=9.488, p=0.001), 
the audiometry value after ITC was lower than the initial 
value (p=0.004), and there was no difference between 
values after ITC and after OCT (p=0.066).
At 8000 Hz (F2, 26=9.715, p=0.001), a statistically 
significant difference was found between initial audiometry 
values and after ITC (p=0.011) and between post ITC and 
post OCT values (p=0.019).
There was a statistically significant difference betwe-
en SRR values in three  audiometry tests (F2, 26=13.208, 
p<0.001). The multiple comparisons procedure showed 
that these differences were present in initial measurements, 
after ITC (p=0.002) and between initial and after OCT value 
(p=0.031) (Fig. 5).
DISCUSSION
Wilson et al. conducted a double-blind placebo-
controlled study that demonstrated a statistically significant 
benefit of systemic corticosteroids for hearing recovery in 
patients with sudden sensorineural hearing loss (SSHL).1 
Other studies have also shown the benefit of systemic 
corticosteroid therapy for hearing loss recovery in SSHL 
patients.3,5,6,7,11 A few researchers, however, have publi-
shed discouraging results as to the benefits of systemic 
corticosteroids compared to placebo.2,4,8
The precise mechanism by which steroids may 
improve hearing remains unknown; both glucocorticoid 
and mineralocorticoid receptors may be found in the inner 
ear.28 A few studies have shown that the main roles of 
steroids in the treatment of SHL are to protect the cochlea 
from the harmful effects of inflammatory mediators such 
as the tumor necrosis factor (TNF-a and NFK-b), which is 
elevated in infection and inflammation,29 to increase co-
chlear blood flow30 thereby avoiding cochlear ischemia,31 
to avoid noise-induced hearing loss,32 and to regulate 
protein synthesis in the inner ear.33 Studies have shown 
that the vascular stria, which regulates Na/K secretion for 
maintaining the endocochlear potential, is a site of injury 
in SHL.34 Systemic corticosteroid therapy improves vascu-
lar stria function and may preserve its morphology,35 and 
therefore its potential for recovering from SHL.
Several studies have shown that intratympanic 
corticosteroids are safe and do not appear to cause any 
histological changes.12,36-40
It has been demonstrated that intratympanic cor-
ticosteroids increase cochlear blood flow,12,36 prevents 
aminoglycoside toxicity41 and improves ionic homeostasis, 
which is necessary for adequate cochlear function.39 Intra-
tympanic corticosteroids protect the vascular stria in otitis 
media.42 Studies of patients with tinnitus have shown that 
intratympanic dexamethasone is not effective for relieving 
symptoms, but has no adverse effects against cochlear 
function, as evidences in otoacoustic emissions.38,39 Other 
studies have also suggested that intratympanic corticoste-
roids might not be beneficial in the treatment of hearing 
loss. These authors suspected that there was a potential risk 
of decreased cochlear function because of intratympanic 
therapy.43 Intratympanic therapy has also been charged 
with causing inflammation to reach the round window.44 
Yang et al. argued that intratympanic therapy was ineffec-
tive for preventing immune mediated labyrinthitis induced 
by the KLH factor in guinea-pigs, and therefore would be 
ineffective in the treatment of SHL.45
Cochlear Pharmacokinetics
Steroids administered intratympanically may attain 
high concentrations in the perilymph, higher than when 
administered intravenously or orally.13,46,47 Using markers 
Figure 5. Comparison between recovery of the SRR after oral and 
intratympanic corticosteroid therapy
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such as phenyl-ammonia (TMPA)48 and peroxidase,49 re-
searchers have demonstrated a non-uniform distribution, 
where higher concentrations were reached close to the 
round window (basal gyrus) compared to the apical gyri. 
Salt showed that substances could reach the vestibule 
by means of extracellular pathways between scalae and 
through the spiral ligament.50,51 These studies and those 
of Parnes13 suggest that there is non-linear flow and inter-
scala pathways for substances administered intratympa-
nically.13,50-52
Studies on Intratympanic corticosteroids for the Treat-
ment of SSHL
Silverstein (1996) published the first report of intra-
tympanic corticosteroid use for the treatment of SSHL,12 
followed by Parnes (1999).13 Several other researchers have 
published their results, mostly after 2001.9,14-21,23-27 Many 
of these papers reported on the benefits of intratympanic 
corticosteroids for the treatment of SSHL in patients where 
systemic therapy failed.
Recent papers have described studies in which 
patients were given intratympanic corticosteroids as the 
therapy of choice or as adjuvant therapy with oral corti-
costeroid therapy.23,24 In most of these studies, the addition 
of intratympanic therapy to oral therapy had no significant 
effect on the recovery of hearing. Lauterman23 compared 
patients that were given intratympanic corticosteroids and 
systemic corticosteroid therapy with another group treated 
only with oral corticosteroid therapy and found no be-
nefit from adding intratympanic corticosteroids. Battista24 
reported a minor improvement following intratympanic 
corticosteroids in SHL patients in a study of 25 patients 
with profound sensorineural hearing loss (90-dB PTA).
Lefebre and Staeker treated 6 SHL with methyl-
prednisolone infused through a microcatheter during 8 
to 10 days. Systemic treatment had failed in all of these 
patients. The tone thresholds of six patients improved on 
average from 16.25 to 25 dB.16 Kopke et al. reported on the 
result of intratympanic microcatheters therapy (62.4 mg/
mL methylprednisolone at 10 ml/hour for 14 days) in the 
treatment of SHL patients; in this study, patients had been 
treated before with oral prednisolone for 2 weeks without 
success. Five of six treated patients showed improved 
hearing, four of which returned to normal hearing status.17
Gouveris treated 40 patients with intratympanic 
corticosteroids in a prospective study of patients in whi-
ch systemic therapy had been unsuccessful. Efficacy was 
lower in patients with profound hearing loss or high-
frequency loss.19
Lauterman et al. (2005) reported the results of a 
prospective study in which a group of SHL patients was 
treated with intratympanic methylprednisolone as the first 
treatment, and was then compared with another group 
undergoing systemic therapy (rheological agents and 
prednisolone). There was no difference in the efficacy of 
both treatments.
Ho et al. (2005) published a randomized placebo-
controlled study of 39 SHL patients in which 29 (74%) 
did not benefit from systemic therapy, and were then 
randomized into two groups; fifteen patients were given 
intratympanic corticosteroids and 14 were given systemic 
therapy. The recovery rate of hearing in the intratympanic 
therapy group was 53%, while it was 7.1% in patients given 
systemic therapy; the improvement criterion was a 30 dB 
gain in PTA. Age, delayed beginning of therapy and sex 
did not alter the response to treatment.20
Battista (2005) treated 25 patients diagnosed with 
profound sensorineural hearing loss; systemic and intra-
tympanic therapy was given jointly (adjuvant therapy). 
Results were generally poor: only 12% (3 of 25) had com-
plete or partial recovery of hearing.24
Slattery et al. published a study of 20 SHL patients 
treated unsuccessfully with systemic therapy, and then 
treated with intratympanic methylprednisolone. A 10dB 
improvement - PTA or 12% discrimination - was seen in 
55% of patients, as well as decreased tinnitus.9
Dallan et al. (2006) treated 8 patients with intratym-
panic methylprednisolone in a prospective study; there was 
a 75% improvement rate after a single injection.26
Choung et al. reported a 38% improvement rate in a 
group of patients treated with intratympanic and systemic 
therapy; another group treated only with systemic therapy 
had a 6.1% improvement rate.25
As the natural history of SHL suggest high recovery 
rates, it is rather difficult to establish whether interventions 
really increase those rates. The natural history of untre-
ated SHL patients has recovery rates ranging from 31% 
to 65%.1,3,4,8 Several reasons may explain these different 
published rates; the best one may be the possibility that 
each author measures successful recovery differently.
A review of studies published to this date shows 
that the definition of success or post-therapy improvement 
may differ significantly between authors. There are no 
established criteria for defining recovery in SHL patients, 
especially in those cases of secondary recovery after failure 
of the first treatment. Recovery criteria may range from 
any improvement in PTA or SRR,14 a 10 dB improvement 
in the PTA or 10% in the SRR,15 or even Wilson et al.’s 
criterion,1 which defines improvement as a 50% recovery 
of the initial loss.24
A metanalysis of the literature would be complicated 
by the huge variation in protocols and data presentation 
of patients. If we apply similar improvement criteria in 
most of these studies, however, one would probably find 
similar recovery rates.
Our recovery rate (about 70%) is similar to that in 
other studies that applied the same criteria for defining 
improvement, the number of injections, their concentration 
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and the type of steroid.
Shaia and Sheehy noted a significant improvement 
in patients treated within a week of the onset of hearing 
loss. However, some patients that started treatment after 
3 months also recovered (10%).53 Fuse et al. found that 
most patients that recovered completely after OCT impro-
ved within 7 to 10 days after starting steroid medication. 
A longer term follow-up of patients (3 months to 2 years) 
showed that none of the patients that did not recover in 
the short term returned to normal hearing status. These 
authors found that corticosteroid-resistant patients conti-
nued to recover poorly in a long term follow-up.6
Ito et al. assessed 90 SHL patients and found that 
patients that recovered within 2 weeks had more chances 
of recovering more completely. Patients that recovered 
poorly within 2 weeks had insignificant further improve-
ment in longer than 1 month monitoring.10
Lefebre reported that 100% of sensorineural SHL pa-
tients treated with corticosteroids recovered within 7 days.16
We excluded patients with Ménière’s disease and 
fluctuating hearing loss because of the difficulty of sepa-
rating treatment as a defining factor for recovery. Contra-
lateral normal hearing was present in 92.82% of patients.
Three patients had diabetes mellitus; the recovery 
rate in these patients was similar to non-diabetic subjects. 
There were no complications in this group of patients; all 
three (21.42%) had type 2 diabetes mellitus and underwent 
systemic 1mg/kg/day prednisolone therapy with the ap-
proval of their assisting physicians.
Chandrasekhar found that 3 of 3 diabetic SHL pa-
tients improved with intratympanic therapy,14 which runs 
opposite to the general feeling that diabetic SHL patients 
would fare worse than non-diabetic subjects.53,54
Patients with vertigo in our study had lower re-
covery rates compared to patients without vertigo. The 
presence of vertigo has been associated with a worse 
prognosis in several studies.2,4,21,52,53
Patients with profound hearing loss had similar re-
covery rates to patients with losses below 90 dB. Pearson’s 
test showed that there were no statistically significant cor-
relations between initial loss (initial PTA) and improvement 
after OCT (r = -0.115, p=0.696) (Fig. 1), and between initial 
loss and improvement after ITC (r = 0.134, p=0.647) (Fig. 
2). Several studies, however, have suggested that patients 
with profound hearing loss have a worse prognosis.2,7,11,24
The PTA of only one patient worsened (defined as 
any worsening in follow-up exams) after injections. Only 
this patient had a mildly worse SRR (defined as any wor-
sening in follow-up exams) after injections. This may be 
explained in part by the fact that this patient had temporary 
perforation with otorrhea.
No other patient had perforation, otitis media, otor-
rhea, otalgia, or vertigo after injections. No other compli-
cations were reported. We reduced partly the limitations 
of this study by choosing a prospective study; it did not, 
however, contain a control group to compare the results 
of treated and untreated patients. This was because all 
available patients for therapy - after unsuccessful systemic 
therapy - chose to enter the study; we found it unethical 
to block access to Intratympanic therapy.
Although we were aware that dexamethasone 
diffuses well through the round window, we chose me-
thylprednisolone because Parnes demonstrated that this 
drug has a higher concentration and remains longer in the 
perilymph after intratympanic administration compared to 
hydrocortisone or dexamethasone.13
Finally, we opted for three injections based on the 
reflections of other authors who ended their studies un-
satisfied with single injection therapy and recommended 
continuous infusion or multiple injections in subsequent 
studies.16,17
CONCLUSION
The recovery rate in this group of patients under-
going salvage treatment (after systemic therapy had failed) 
was 71.4%; this was a 20 dB improvement in the tritonal 
mean or 20% in the SRR. This study included only patients 
in whom systemic therapy had failed, and showed that 
three intratympanic methylprednisolone injections raised 
the tone thresholds and SRR in this group of patients with 
SSHL that did not benefit from oral corticosteroid therapy, 
evidence that this novel technique is a modern alternative 
for the treatment of patients with SSHL.
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